Track Biomerica, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Biomerica, Inc. BMRA · Stock Open Biomerica, Inc. in new tab

2.48 USD
EPS
-1.30
P/B
2.72
ROE
-112.10
Beta
0.37
Loading chart...
Key Metrics
Earnings dateOct. 21, 2026
EPS-1.30
Book Value0.82
Price to Book2.72
Debt/Equity90.61
% Insiders21.759%
Growth
Revenue Growth0.17%
Estimates
Forward P/E5.74
Forward EPS0.39

DCF Valuation

Tweak assumptions to recompute fair value for Biomerica, Inc. (BMRA)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Biomerica, Inc. Logo Biomerica, Inc. Analysis (BMRA)

United States Health Care Official Website Stock

Is Biomerica, Inc. a good investment? Biomerica, Inc. (BMRA) is currently trading at 2.48 USD.

Earnings Schedule: Biomerica, Inc. is expected to release its next earnings report on Oct. 21, 2026. The market consensus estimate for Forward EPS is 0.39.

Investor FAQ

Does Biomerica, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Biomerica, Inc.?

Biomerica, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Oct. 21, 2026. The company currently has a trailing EPS of -1.30.

Company Profile

Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing of diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases in North America, Asia, Europe, the Middle East, and South America. The company offers diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients to aid in the diagnosis of diseases, food intolerances, and other medical conditions, as well as detect and measure the presence and levels of specific bacteria, hormones, antibodies, antigens, and other substances that may exist in the human body at extremely low concentrations through clinical laboratories and in point-of-care settings, including physicians' offices and over-the-counter channels. It also provides contract development and manufacturing services to third parties. In addition, the company commercializes inFoods IBS product through physician-directed and laboratory-based channels, such as third-party reimbursement pathways. Further, it is involved in the development and optimization of immunoassays, enzyme-linked immunosorbent assays, rapid diagnostic tests, and related diagnostic technologies; and research, development, commercialization of diagnostic-guided therapy (DGT) products to treat gastrointestinal diseases, such as irritable bowel syndrome (IBS), and other inflammatory diseases. Additionally, the company offers EZ detect colon disease home test; Aware Breast Self-Exam product; and hp+detect, a diagnostic test designed to detect Helicobacter pylori (H. pylori) bacteria in the gastrointestinal tract. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

Exchange Ticker
NCM (Australia) BMRA
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Nov. 14, 1994 1:2
April 21, 2025 1:8
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion